HELIX Pharmaceutical Catalogue
A professional pharmaceutical catalogue featuring clear product specifications, verified authenticity codes and dependable customer support.
Important information
The products displayed on this website are presented strictly for informational and educational purposes, helping visitors understand their descriptions, features and specifications. No products are offered for sale through this website, and no product orders or payments are accepted through this platform.
Where permitted by applicable law, HELIX may provide contact details for independent, appropriately licensed third-party providers. Visitors may contact these providers directly to enquire about lawful availability and eligibility requirements. Any supply is subject to the provider's assessment, applicable regulations, and verification of all required documentation, which may include a valid prescription, professional licence, identification or other authorisation. A referral does not guarantee availability, eligibility or supply.
The information on this website does not constitute medical advice, a prescription or a recommendation to use any product. Displaying a product does not establish its regulatory approval, safety or suitability for an individual. Please consult an appropriately qualified healthcare professional for personal medical advice.
Independent provider referral
HELIX remains an information, education and verification platform. Where legally appropriate, our separate directory can identify independent providers whose stated registration details have been checked against an official source.
01Registration shownRegulator, number, jurisdiction and last-checked date.
02Independent responsibilityThe provider handles assessment, documentation and any lawful supply.
03No guaranteeA referral does not guarantee availability, eligibility or supply.
The collection
Explore our pharmaceutical range with product images, formulation details, stated strengths and complete kit contents.
Browse by category
Products for this category will appear here once added.
Weight Loss
HELIX Retatrutide is presented as a 40mg injection pen kit. The listed formulation is a triple agonist acting on GLP-1, GIP and glucagon receptor pathways for controlled metabolic research.
| Total dose | 40mg |
|---|---|
| Pens per kit | 1 |
| Doses | 4 × 10mg |
| Listed increments | 2.5 / 5 / 7.5 / 10mg |
| Reference frequency | Once weekly |
| Mechanism | Triple agonist (GLP-1, GIP, glucagon) |
| Kit contents | 1 pen; 12 disposable needles; 1 information booklet. |
Weight Loss
HELIX Tirzepatide is presented as a 40mg injection pen kit. Its listed dual-agonist mechanism targets GLP-1 and GIP receptor pathways for metabolic and appetite-related research.
| Total dose | 40mg |
|---|---|
| Pens per kit | 1 |
| Doses | 4 × 10mg |
| Listed increments | 2.5 / 5 / 7.5 / 10mg |
| Reference frequency | Once weekly |
| Mechanism | Dual agonist (GLP-1, GIP) |
| Kit contents | 1 pen; 12 disposable needles; 1 information booklet. |
Weight Loss
HELIX Semaglutide is presented as an 8mg two-pen kit, with 4mg in each pen. The formulation is identified as a GLP-1 receptor agonist for controlled metabolic research.
| Total dose | 8mg (2 × 4mg) |
|---|---|
| Pens per kit | 2 |
| Listed increments | 0.25 / 0.5 / 0.75 / 1mg |
| Reference frequency | Once weekly |
| Mechanism | GLP-1 receptor agonist |
| Kit contents | 2 pens; 12 disposable needles; 1 information booklet. |
Weight Loss
HELIX CagriSema combines separately supplied Semaglutide and Cagrilintide pens. The formulation pairs a GLP-1 receptor agonist with a long-acting amylin analogue for dual-pathway appetite and metabolic research.
| Pen 1 | Semaglutide 4mg |
|---|---|
| Pen 2 | Cagrilintide 4mg |
| Pen 1 increments | 0.25 / 0.5 / 0.75 / 1mg |
| Pen 2 increments | 0.25 / 0.5 / 0.75 / 1mg |
| Reference frequency | Once weekly (same day) |
| Kit contents | 2 pens; 12 disposable needles; 1 information booklet. |
Weight Loss
HELIX Cagri Reta combines separately supplied Retatrutide and Cagrilintide pens. The kit pairs a triple-agonist formulation with an amylin analogue for dual-pathway metabolic and appetite-related research.
| Pen 1 | Retatrutide 40mg |
|---|---|
| Pen 2 | Cagrilintide 4mg |
| Pen 1 increments | 2.5 / 5 / 7.5 / 10mg |
| Pen 2 increments | 0.25 / 0.5 / 0.75 / 1mg |
| Reference frequency | Once weekly (same day) |
| Kit contents | 2 pens; 12 disposable needles; 1 information booklet. |
Recovery
HELIX Somatotropin HGH is presented as a 90 IU / 30 mg injection pen kit containing somatotropin (HGH). This entry identifies the formulation and supplied kit format for growth-hormone information.
| Total dose | 90 IU / 30 mg |
|---|---|
| Format | Injection Pen Kit |
| Compound | Somatotropin (HGH) |
| Kit contents | 1 pen; supplied needles; 1 information booklet. |
Recovery
HELIX HCG is presented as a 5000 IU / 3 mL informational product entry with a labelled click-volume reference. This page is for general education and verification context only.
| Total dose | 5000 IU / 3 mL |
|---|---|
| Reference conversion | 1 click = 16 IU |
| Format | Injection Pen Kit |
| Compound | Human chorionic gonadotropin (HCG) |
Recovery
HELIX BPC-157 & TB-500 is presented as a 40mg combined-peptide injection pen kit. The listed blend contains 12mg BPC-157 and 28mg TB-500 for laboratory recovery and tissue-response research.
| Total dose | 40mg |
|---|---|
| BPC-157 content | 12mg (30%) |
| TB-500 content | 28mg (70%) |
| Format | Injection Pen Kit |
| Kit contents | 1 pen; 12 disposable needles; 1 information booklet. |
Recovery
HELIX Biotin is presented as a 40mg injection pen kit containing biotin, also known as Vitamin B7. The catalogue entry is intended for nutritional, metabolic and cosmetic research reference.
| Total dose | 40mg |
|---|---|
| Compound | Biotin (Vitamin B7) |
| Format | Injection Pen Kit |
| Kit contents | 1 pen; 12 disposable needles; 1 information booklet. |
Recovery
HELIX NAD+ & NMN combines 600mg NAD+ and 400mg NMN in one 1000mg injection pen. The listed 60:40 composition is presented for cellular-energy, metabolism and longevity research.
| Total dose | 1000mg |
|---|---|
| NAD+ content | 600mg (60%) |
| NMN content | 400mg (40%) |
| Doses | 8 × 125mg |
| Reference frequency | Twice weekly |
| Kit contents | 1 pen; 12 disposable needles; 1 information booklet. |
Recovery
HELIX NAD+ & B12 combines NAD+ with Vitamin B12 in a single injection pen kit. The source-listed total dose is 1008mg, presented for cellular-energy, mitochondrial and neurological research.
| Total dose | 1008mg |
|---|---|
| Compounds | NAD+ and Vitamin B12 |
| Format | Injection Pen Kit |
| Kit contents | 1 pen; 12 disposable needles; 1 information booklet. |
Anabolic
HELIX TRT 600mg is presented as a testosterone cypionate injection pen kit for information and verification purposes. The package displays a reusable aluminium pen, 10 sterile needles and an instruction booklet. The click guide below is a labelled pen-volume reference only and is not personal dosing advice.
| Displayed compound | Testosterone cypionate |
|---|---|
| Displayed strength | 600mg |
| Format | Injection Pen Kit |
| Kit contents | 1 reusable aluminium pen; 10 sterile needles; 1 instruction booklet. |
| Click dosing guide | 5 clicks = 0.05 mL = 10 mg; 10 clicks = 0.10 mL = 20 mg; 15 clicks = 0.15 mL = 30 mg; 20 clicks = 0.20 mL = 40 mg; 25 clicks = 0.25 mL = 50 mg; 30 clicks = 0.30 mL = 60 mg; 35 clicks = 0.35 mL = 70 mg; 40 clicks = 0.40 mL = 80 mg; 45 clicks = 0.45 mL = 90 mg; 50 clicks = 0.50 mL = 100 mg |
| Important note | This guide describes labelled click-volume conversion only. Medical assessment and professional supervision are required before any use. |
Cosmetic
HELIX Melanotan II is presented as a 20mg nasal spray containing the MT2 peptide. The intranasal format is identified for pigmentation and cosmetic research reference.
| Total dose | 20mg |
|---|---|
| Format | Nasal Spray |
| Route | Intranasal |
| Compound | Melanotan II (MT2) |
| Kit contents | 1 nasal-spray bottle; 1 information booklet. |
Cosmetic
HELIX Glow Skin is presented as a 112mg triple-peptide injection pen containing 80mg GHK-Cu, 16mg BPC-157 and 16mg TB-500. The composition is listed for cosmetic, skin and tissue-response research.
| Total dose | 112mg |
|---|---|
| GHK-Cu content | 80mg |
| BPC-157 content | 16mg |
| TB-500 content | 16mg |
| Doses | 40 × 2.8mg |
| Reference frequency | Once daily (40 days, then 30-day break) |
| Route | Subcutaneous |
| Kit contents | 1 pen; 12 disposable needles; 1 information booklet. |
Product authenticity
Reveal the security code on your HELIX product and enter it here. The first successful check is time-stamped, while later checks are clearly marked as previously verified.
Verify your productHow it works
Review product imagery and structured technical fields without clutter.
Use the printed security code on the product box to confirm a record and see its first-check status.
Where legally appropriate, use the separate directory to check independent provider registration information.
Questions
